The FDA has approved Gemtesa® for men with overactive bladder symptoms receiving pharmacological therapy for BPH.

Prostate cancer that has become resistant to hormone therapy could be treated using a new drug that is currently in clinical ...

Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive ...

A Dundalk-area man is the first person in Canada to receive a new, publicly funded treatment that better targets prostate cancer cells and is shown to prolong life.

Drug treatment of BPH was initially viewed with suspicion by urologists, but has gradually achieved widespread acceptance, with excellent consequences for patients. Urologists had further ...

Prostate cancer that has become resistant to hormone therapy could be treated using a new drug that is currently in clinical trials for ovarian and bile duct cancer, according to research published in ...

The Food and Drug Administration (FDA) has approved Gemtesa ® (vibegron) for the treatment of overactive ... on pharmacological therapy for benign prostatic hyperplasia (BPH).

Over the coming months, it is anticipated Pluvicto will be available for eligible patients at most of Ontario’s Cancer ...

Dr. Niti Navanimitkul, MD, from the Urology Center at Bangkok Hospital Pattaya gave an informative presentation to the ...